Total sales were $6.05 billion for the third quarter of 2009, compared to $5.94 billion for the same quarter of 2008.
Net income attributable to the company for the nine months ended September 30, 2009 was $6.40 billion, or $3.03 per diluted share, compared to $6.16 billion, or $2.85 per diluted share, for the nine months ended September 30, 2008.
Total sales were $17.33 billion for the nine months ended September 30, 2009, compared to $17.82 billion for the prior-year period.
Richard Clark, chairman, president and CEO of Merck, said: "Growth of key products, Januvia, Janumet, Isentress and Singulair, plus continued expense management allowed Merck to deliver strong third quarter results. While focused on the day-to-day business priorities that are fundamental to our success, we're also primed for our pending merger with Schering-Plough, and the benefits it will bring to patients around the world."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index